Human epidermal growth factor receptor 2/3 (HER2/HER3) expression in higher-grade meningioma

被引：0
|
作者：
Mair, Maximilian
Tomasich, Erwin
Paiato, Christina
Widhalm, Georg
Eckert, Franziska
Sahm, Felix
Hainfellner, Johannes A.
Berghoff, Anna Sophie
Preusser, Matthias
机构：
[1] Med Univ Vienna, Dept Med 1, Div Oncol, Vienna, Austria
[2] Med Univ Vienna, Dept Neurosurg, Vienna, Austria
[3] Med Univ Vienna, Dept Radiat Oncol, Vienna, Austria
[4] Heidelberg Univ, Inst Pathol, Dept Neuropathol, Heidelberg, Germany
[5] German Canc Res Ctr, German Consortium Translat Canc Res DKTK, Clin Cooperat Unit Neuropathol, Heidelberg, Germany
[6] Med Univ Vienna, Dept Neurol, Div Neuropathol & Neurochem, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14063
引用
收藏
页数：1
相关论文
共 50 条
  • [41] AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
    Zhaomei Mu
    Teresa Klinowska
    Xiaoshen Dong
    Emily Foster
    Chris Womack
    Sandra V Fernandez
    Massimo Cristofanilli
    Journal of Experimental & Clinical Cancer Research, 33
  • [42] AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
    Mu, Zhaomei
    Klinowska, Teresa
    Dong, Xiaoshen
    Foster, Emily
    Womack, Chris
    Fernandez, Sandra V.
    Cristofanilli, Massimo
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2014, 33
  • [43] Draft recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer will decrease HER2 positivity rates
    Johnson, Eric
    Gulbahce, Evin
    CANCER RESEARCH, 2018, 78 (04)
  • [44] Prognostic Significance of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Esophageal and Gastric Cancer
    Chan, David S.
    Reid, Tom D.
    Blackshaw, Guy
    Crosby, Tom
    Lewis, Wyn G.
    GASTROENTEROLOGY, 2012, 142 (05) : S528 - S528
  • [45] Overexpression of HER2/HER3 and clinical feature of ovarian cancer
    Chung, Ye Won
    Kim, Seongmin
    Hong, Jin Hwa
    Lee, Jae Kwan
    Lee, Nak Woo
    Lee, Young Seok
    Song, Jae Yun
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (05)
  • [46] Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients
    Ananiev, Julian
    Aleksandrova, Elina
    Skerleva, Desislava
    Gulubova, Maya
    Chokoeva, Anastasiya
    Lotti, Torello
    Wollina, Uwe
    Tchernev, Georgi
    Kontic, Milica
    Stojsic, Jelena
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2015, 165 (15-16) : 315 - 321
  • [47] Mutant HER2 needs mutant HER3 to be an effective oncogene
    Trenker, Raphael
    Diwanji, Devan
    Jura, Natalia
    CELL REPORTS MEDICINE, 2021, 2 (08)
  • [48] HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer
    Saddawi-Konefka, Robert
    Schokrpur, Shiruyeh
    Lui, Asona J.
    Gutkind, J. Silvio
    CANCER JOURNAL, 2022, 28 (05): : 339 - 345
  • [49] Functional genomics of HER2 and HER3 mutations and response to neratinib
    Hanrahan, Aphrothiti J.
    Hyman, David M.
    Sfakianos, John
    Jones, Alexis
    Ramirez, Ricardo
    Johnsen, Hannah
    Lyer, Gopakumar
    Al-Ahmadie, Hikmat A.
    Bajorin, Dean
    Bochner, Bernard H.
    Coleman, Jonathan A.
    Rosenberg, Jonathan E.
    Berger, Michael F.
    Chandarlapaty, Sarat
    Baselga, Jose
    Solit, David B.
    CANCER RESEARCH, 2015, 75
  • [50] Novel agents that downregulate EGFR, HER2, and HER3 in parallel
    Ferreira, Renan Barroso
    Law, Mary Elizabeth
    Jahn, Stephan Christopher
    Davis, Bradley John
    Heldermon, Coy Don
    Reinhard, Mary
    Castellano, Ronald Keith
    Law, Brian Keith
    ONCOTARGET, 2015, 6 (12) : 10445 - 10459
12345